Daily non-political popular news in brief.
Vitamin D, variations in its receptor and prostate cancer
03-19-2007 · EurekAlert!Results of this study by Haojie Li and colleagues suggest that vitamin D deficiency is common among men in the US, and that vitamin D status and genetic variation in the VDR gene affect prostate cancer risk.
Read more »
Keywords: vitamin, variations, receptor, prostate, cancer, variation
« Previous | Next »
Similar news on "Vitamin D, variations in its receptor and prostate cancer":
- Vitamin D, variations in its receptor, and prostate cancer
03-19-2007 · EurekAlert!
Results of this study by Haojie Li and colleagues suggest that vitamin D deficiency is common among men in the US, and that vitamin D status and genetic variation in the VDR gene affect prostate cancer risk.
Similar news · Read more »
- Survival data presented from phase II study of hormone-resistant prostate cancer patients
09-25-2007 · EurekAlert!
The results from a randomized, double-blind, placebo-controlled, Phase II study of ZD4054 -- a specific endothelin A receptor antagonist -- were delivered today at the 14th European Congress of Clinical Oncology (ECCO, 23-27 Sept., Barcelona). The data presented today for ZD4054, an investigational compound in development for the treatment of men with hormone-resistant prostate cancer, showed no differences in progression-free survival but did report encouraging overall survival data.
Similar news · Read more »
- Sunshine pill for prostate cancer in 2009
01-16-2007 · EurekAlert!
A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
Similar news · Read more »
- New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer
02-16-2007 · EurekAlert!
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.
Similar news · Read more »
- New genetic variant associated with prostate cancer in African-Americans
10-31-2007 · EurekAlert!
Two tiny genetic variations may provide the best clues yet for finding more precise ways to estimate prostate cancer risk and improve screening and early detection for men of African descent.
Similar news · Read more »
- Jefferson scientists find aging gene also protects against prostate cancer development
11-27-2006 · EurekAlert!
Cancer researchers have found that a gene that is involved in regulating aging also blocks prostate cancer cell growth. They have shown that the enzyme SIRT1 can block the growth of treatment-resistant prostate cancer cells that overexpress a mutation for the androgen receptor. The scientists hope the newly found connection will aid in better understanding the development of prostate cancer and lead to new drugs against the disease.
Similar news · Read more »
- Drug slows prostate tumor growth by keeping vitamin A active
11-06-2007 · EurekAlert!
A novel compound that blocks the breakdown of retinoic acid, derived from vitamin A, is a surprisingly effective and "promiscuous" agent in treating animal models of human prostate cancer, say investigators from the University of Maryland, Baltimore.
Similar news · Read more »
- Researchers chart the genetic mechanisms behind the genesis of fat cells
11-06-2007 · EurekAlert!
Obesity is a well known risk factor for prostate, breast and colon cancer, but recent studies have shown that a protein responsible for generating fat cells also plays an important role in cancer. Researchers at the Genome Institute of Singapore have conducted, for the first time, a genome-wide analysis of how the protein, called perixosome proliferator-activated receptor gamma, turns on various genes related to obesity.
Similar news · Read more »
- Pro-vitamin E shown to be active against breast cancer cells
12-07-2006 · EurekAlert!
A precursor of vitamin E has been shown to be effective against breast cancer cell lines which over-express human epidermal growth factor receptor (HER2).
Similar news · Read more »
- BRCA2 carriers at increased risk for deadly form of prostate cancer
06-12-2007 · EurekAlert!
Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online June 12 in the Journal of the National Cancer Institute.
Similar news · Read more »
